-
公开(公告)号：EP1363627A2
公开(公告)日：2003-11-26
申请号：EP02719864.7
申请日：2002-02-18
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/436
CPC分类号： A61K31/436 , A61K31/337 , A61K31/4196 , A61K31/439 , A61K31/4745 , A61K31/475 , A61K31/502 , A61K31/555 , A61K31/5685 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2300/00
摘要： Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
-
2.发明公开
公开(公告)号：EP1667721A2
公开(公告)日：2006-06-14
申请号：EP04765555.0
申请日：2004-09-23
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BOLD, Guido , BRUEGGEN, Josef, Bernhard , HUANG, Jerry, Min-Jian , KINDER, Frederick, Ray , LANE, Heidi , LATOUR, Elisabeth, Jeanne , MANLEY, Paul, William , WOOD, Jeanette, Marjorie
CPC分类号： A61K45/06
摘要： The invention relates to a combination therapy for treating patients suffering from diseases characterized by cell proliferation and infiltration of inflammatory cells, coronary diseases, hypertension, renal diseases, diabetes, or ocular diseases and conditions. The patient is treated with a combination of: (a) a VEGF inhibitor compound; and (b) one or more second therapeutic agents selected from the group consisting of: i. angiostatic steroids; ii. photosensitizers; iii. implants containing corticosteroids; iv. AT1 receptor antagonists; V. ACE inhibitors; vi. cyclooxygenase inhibitors; vii. IGF-IR inhibitors; viii. mTOR kinase inhibitors; ix. somatostatin receptor antagonists; X. P13K inhibitors; A. Raf kinase inhibitors; xii. PKC inhibitors; xiii. integrin antagonists; xiv. endogenous anti-anglogenic molecules; and xv. PEDF and analogs.
-
3.发明公开PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR 审中-公开一mTOR抑制剂和Raf激酶抑制剂的药物组合
公开(公告)号：EP2023956A2
公开(公告)日：2009-02-18
申请号：EP07725034.8
申请日：2007-05-09
申请人： Novartis AG
发明人： LANE, Heidi
CPC分类号： A61K45/06 , A61K31/00 , A61K2300/00
摘要： A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.
-
公开(公告)号：EP1983984A2
公开(公告)日：2008-10-29
申请号：EP07711417.1
申请日：2007-01-31
申请人： NOVARTIS AG
发明人： BERG, William , BENEDETTO, John , ELMROTH, Ingrid , LANE, Heidi , LEBWOHL, David , SELLERS, William , STUMM, Michael
IPC分类号： A61K31/436 , A61K31/365 , A61K31/351 , A61P35/00 , A61P25/00
CPC分类号： A61K31/351 , A61K31/365 , A61K31/436 , C07D498/16
摘要： Rapamycin derivatives for use in the treatment of neurocutaneous disorders.
摘要翻译： 雷帕霉素衍生物用于治疗神经性皮肤疾病。
-
公开(公告)号：EP1976530A1
公开(公告)日：2008-10-08
申请号：EP07702745.6
申请日：2007-01-12
申请人： NOVARTIS AG
发明人： LANE, Heidi , O'REILLY, Terence
IPC分类号： A61K31/519 , A61K31/436 , A61P35/00 , A61P17/06
CPC分类号： A61K45/06 , A61K31/436 , A61K31/519 , A61K2300/00
摘要： Use of a combination of an mTOR inhibitor and an antifolate compound.
-
公开(公告)号：EP1909794A2
公开(公告)日：2008-04-16
申请号：EP06764229.8
申请日：2006-07-19
申请人： Novartis AG
发明人： MANLEY, Paul, W. , LANE, Heidi
IPC分类号： A61K31/506 , A61K31/436 , A61P35/00
CPC分类号： A61K45/06 , A61K31/436 , A61K31/506 , A61K2300/00
摘要： The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound, and b) an mTOR kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.
-
7.发明公开P53 WILD-TYPE AS BIOMARKER FOR THE TREATMENT WITH MTOR INHIBITORS IN COMBINATION WITH A CYTOTOXIC AGENT 审中-公开P53野生型作为与mTOR抑制剂治疗的生物标志物结合的细胞毒性剂
公开(公告)号：EP1721007A2
公开(公告)日：2006-11-15
申请号：EP05715457.7
申请日：2005-02-22
申请人： Novartis AG , Novartis Pharma GmbH , Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
发明人： BEUVINK, Iwan , BOULAY, Anne , LANE, Heidi , O'REILLY, Terence , THOMAS, George
IPC分类号： C12Q1/68
CPC分类号： G01N33/5748 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N2800/52
摘要： Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.
-
公开(公告)号：EP1983984B1
公开(公告)日：2018-03-07
申请号：EP07711417.1
申请日：2007-01-31
申请人： Novartis AG
发明人： BERG, William , BENEDETTO, John , ELMROTH, Ingrid , LANE, Heidi , LEBWOHL, David , SELLERS, William , STUMM, Michael
IPC分类号： A61K31/436 , A61K31/365 , A61K31/351 , A61P35/00 , A61P25/00
CPC分类号： A61K31/351 , A61K31/365 , A61K31/436 , C07D498/16
摘要： Rapamycin derivatives for use in the treatment of neurocutaneous disorders.
-
9.发明公开BIOMARKERS FOR SENSITIVITY OF PROLIFERATIVE DISEASES TO MTOR INHIBITORS 审中-公开生物标记EMPFLINDLICHKEIT增生性疾病AGAINST mTOR抑制剂
公开(公告)号：EP1709449A1
公开(公告)日：2006-10-11
申请号：EP04804145.3
申请日：2004-12-21
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： G01N33/68 , G01N33/574
CPC分类号： G01N33/5008 , G01N33/5011 , G01N33/5091 , G01N33/574 , G01N33/57496 , G01N33/68 , G01N33/6842 , G01N2800/52
摘要： Disclosed is a method for determining the sensitivity of a proliferate disease in a subject to treatment with an mTOR inhibitor, comprising determining the level of expression and/or phosphorylation state of S6 in a sample derived from the subject, as well as related methods of treatment and uses.
-
10.发明公开
公开(公告)号：EP1682181A2
公开(公告)日：2006-07-26
申请号：EP04765542.8
申请日：2004-09-23
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BOLD, Guido , BRUEGGEN, Josef, Bernhard , HUANG, Jerry, Min-Jian , KINDER, Frederick, Ray, Jr. , LANE, Heidi , LATOUR, Elisabeth, Jeanne , MANLEY, Paul, William , WOOD, Jeanette, Marjorie
IPC分类号： A61K45/06 , A61K31/502
CPC分类号： A61K45/06 , A61K31/502 , A61K2300/00
摘要： The present invention relates to a combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis. The patient is treated with a VEGF inhibitor compound; and one or more chemotherapeutic agents.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.013 秒)
